Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. QIAGEN N.V.
  6. News
  7. Summary
    QGEN   NL0012169213


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

QIAGEN N : first-quarter profit tops expectations on growth in non-COVID-19 products

05/03/2021 | 05:13pm EDT
Economy Minister Andreas Pinkwart and Health Minister Karl-Josef Laumann of the German state Northrhine Westphalia visit a testing company Qiagen, in Hilden

(Reuters) - U.S.-German genetic testing company Qiagen NV reported slightly better-than-expected quarterly earnings on Monday as sales growth in its non-coronavirus products added to high demand for COVID-19 tests.

Qiagen's products include several types of COVID-19 tests that helped it to boost sales over the past year and recover from a difficult 2019 that included profit warnings, a slump in China business and a CEO departure.

The company said it plans to keep growing sales even after the pandemic by broadening its portfolio and making sure each coronavirus-related test has other applications as well.

"We have made multiple product expansions to our non-COVID related portfolio, including the launch of a Lyme disease test," Qiagen's Chief Executive Thierry Bernard said in a statement.

The company said first-quarter adjusted earnings rose to 65 cents per share on a currency-adjusted basis, beating the 63 cents on average forecast by analysts in a Vara Research poll, as research laboratories around the world have returned to work and clinical labs moved beyond COVID-19 testing.

"This performance was particularly driven by 16% constant currency growth in sales of non-COVID product groups that represented 64% of our sales," Bernard said.

Qiagen also confirmed its 2021 forecast for adjusted earnings of $2.42 to $2.46 per share and net sales growth of 18% to 20% at constant exchange rates.

($1 = 0.8262 euros)

(Reporting by Zuzanna Szymanska in Gdansk; Editing by Bill Berkrot)

ę Reuters 2021
All news about QIAGEN N.V.
05/07DGAP-PVRá : QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG ..
05/06QIAGEN Ná : Clinical Laboratory Tests Market To Demonstrate Massive Growth By 20..
05/06QIAGEN NVá : Buy rating from Deutsche Bank
05/05QIAGEN NVá : Receives a Buy rating from Kepler Cheuvreux
05/05QIAGEN Ná : And subsidiaries u.s. gaap quarterly report for the period ended mar..
05/05QIAGEN Ná : Chief Financial Officer
05/05DGAP-CMSá : QIAGEN N.V.: Release according to Article 50 of the WpHG [the German..
05/05QIAGEN N.V. : Release according to Article 50 of the WpHG [the German Securities..
05/04DGAP-PVRá : QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG ..
05/04QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
More news
Financials (USD)
Sales 2021 2 268 M - -
Net income 2021 482 M - -
Net Debt 2021 802 M - -
P/E ratio 2021 22,6x
Yield 2021 -
Capitalization 10 897 M 10 897 M -
EV / Sales 2021 5,16x
EV / Sales 2022 5,11x
Nbr of Employees 5 750
Free-Float 93,0%
Duration : Period :
QIAGEN N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 58,33 $
Last Close Price 47,64 $
Spread / Highest target 51,1%
Spread / Average Target 22,4%
Spread / Lowest Target -13,9%
EPS Revisions
Managers and Directors
Thierry Bernard Chief Executive Officer & Managing Director
Roland Sackers Chief Financial Officer & Managing Director
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN N.V.-9.86%10 897
MODERNA, INC.56.17%65 346
LONZA GROUP AG1.51%47 533
CELLTRION, INC.-25.77%32 687
SEAGEN INC.-20.36%25 314